Tirzepatide produces greater average weight loss; semaglutide has the deeper long-term safety record and established cardiovascular outcomes data. Neither is universally "better."
Both are available through Luma Health as compounded medications: semaglutide at $197/month and tirzepatide at $297/month, with a real physician evaluation to help determine the right fit for you.
Semaglutide and tirzepatide are the two leading GLP-1-class medications for weight management in 2026, and patients researching either one eventually run into the same question: which is actually better? The honest answer is that they differ in meaningful ways, and the right choice depends on your specific health profile, not a single "winner."
Mechanism: One Receptor vs. Two
Semaglutide is a GLP-1 receptor agonist — it mimics a single gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. Tirzepatide activates both the GLP-1 and GIP receptors, a dual mechanism that appears to produce somewhat greater average weight loss and larger A1C improvements in head-to-head trial data. The added GIP activity is the core mechanistic difference driving tirzepatide's stronger average results.
Efficacy: What the Trials Show
| Semaglutide | Tirzepatide | |
|---|---|---|
| Trial | STEP 1 | SURMOUNT-1 |
| Avg. weight loss | ~14.9% at 68 weeks | ~20-22.5% at 72 weeks Higher |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Dosing frequency | Weekly | Weekly |
| Cardiovascular outcomes | Strong — SELECT trial Established | Developing |
| Years on market | Since 2017 (class since 2005) | Since 2022 |
| Luma Health price | $197/month, flat | $297/month, flat |
These percentages are trial averages, not individual guarantees — actual results vary by starting weight, dose, adherence, and individual biology.
Side Effects: Broadly Similar
Both medications share a similar gastrointestinal side-effect profile — nausea, diarrhea, constipation, and vomiting are the most commonly reported, typically most pronounced during dose titration and easing as the body adjusts. Neither medication has a clearly better tolerability record in head-to-head comparisons; individual response varies more than the average difference between the two drugs.
Safety Record: Semaglutide's Longer History
The GLP-1 receptor agonist class has been FDA-approved since 2005, and semaglutide specifically since 2017 for diabetes, giving clinicians a longer real-world safety track record. The SELECT trial specifically demonstrated that semaglutide reduces major adverse cardiovascular events in patients with established heart disease — a meaningful data point for that population. Tirzepatide, approved more recently, doesn't yet have an equivalent completed cardiovascular outcomes trial, though one is in progress.
Matching the Medication to You
- Have established cardiovascular disease or significant risk factors
- Want the medication with the longest real-world track record
- Have more moderate weight-loss goals
- Prioritize the lower monthly cost
- Have significant weight to lose and want the highest average efficacy
- Have type 2 diabetes and want maximum A1C improvement
- Haven't responded as well as expected to semaglutide
The right choice depends on your BMI, cardiovascular risk factors, diabetes status, and personal response — which is why Luma Health starts every patient with a real medical evaluation from a licensed provider, rather than defaulting everyone to the same medication.
Let a provider help you
choose the right fit
Compounded semaglutide at $197/month or tirzepatide at $297/month, flat — with a real physician evaluation to match the medication to your health profile.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not necessarily. Tirzepatide shows greater average weight loss in trials, but semaglutide has a longer safety track record and established cardiovascular outcomes data via the SELECT trial. The better choice depends on individual health history and goals.
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, a dual mechanism that appears to drive its somewhat greater average efficacy in head-to-head data.
Both share a broadly similar gastrointestinal side-effect profile, most pronounced during dose titration. Neither has a clearly better tolerability record; individual response varies more than the average difference between the two.
Semaglutide, via the SELECT trial, which demonstrated reduced major adverse cardiovascular events in patients with established heart disease. Tirzepatide's equivalent cardiovascular outcomes data is still developing.
This is a reasonable conversation to have with your prescribing provider if you haven't seen the response you expected after an adequate trial period at an appropriate dose. Switching should be guided by your provider rather than done independently.
Neither by default. Every Luma Health patient starts with a real medical evaluation from a licensed provider who considers your BMI, health history, and goals before recommending compounded semaglutide ($197/month) or tirzepatide ($297/month).
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PubMed 37385275
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database